- Home
- ASTS vs ROIV Comparison
ASTS vs ROIV Comparison
Compare ASTS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTS | ROIV |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United Kingdom |
| Employees | 578 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASTS | ROIV |
|---|---|---|
| Price | $93.35 | $27.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $59.37 | $27.44 |
| AVG Volume (30 Days) | ★ 10.8M | 6.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $1,251.34 | N/A |
| Revenue Next Year | $278.26 | $400.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.22 | $8.73 |
| 52 Week High | $129.89 | $29.20 |
Technical Indicators
Market Signals| Indicator | ASTS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 61.88 |
| Support Level | $65.77 | $20.46 |
| Resistance Level | $102.79 | $27.94 |
| Average True Range (ATR) | 7.18 | 0.88 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 63.01 | 50.34 |
Price Performance
Historical ComparisonAbout ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.